Keynote-905 : A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Surgical<br/>TrialTypeSurgical
Trial

ThreePhase Three

18+Age Over 18

Urinary System<br/>CancersCancer LocationUrinary System
Cancers

Surgical,Systemic therapy | Urinary systemBladder

Trial Overview Read MoreRead more

This phase III trial is evaluating a type of bladder surgery alone and in combination with immunotherapy (Pembrolizumab) in patients with muscle-invasive bladder cancer.
 

This trial is treating patients with muscle invasive bladder cancer.

This is a systemic therapy and surgical trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer

Commercial Sponsor

Merck

Summary

Eligible patients will be randomised to receive standard of care surgery alone OR in combination with 3 preoperative cycles of pembrolizumab and 14 cycles of postoperative pembrolizumab.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital Medical Oncology
Box Hill
Lauren Mitchell
lauren.mitchell@monash.edu
03 9094 9544

Monash Health, Medical Oncology
Clayton
Genitourinary Research Study Coordinator
gu.oncresearch@monashhealth.org
0436387664

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next